KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST

Sabrina Rossi, Daniela Gasparotto, Rosalba Miceli, Luisa Toffolatti, Giovanna Gallina, Enrico Scaramel, Alessandra Marzotto, Elena Boscato, Luca Messerini, Italo Bearzi, Guido Mazzoleni, Carlo Capella, Gianluigi Arrigoni, Aurelio Sonzogni, Angelo Sidoni, Luigi Mariani, Paola Amore, Alessandro Gronchi, Paolo G. Casali, Roberta MaestroAngelo P. Dei Tos

Research output: Contribution to journalArticle

Abstract

The mutation status of KIT or PDGFRA notoriously affects the response of advanced gastrointestinal stromal tumors (GISTs) to tyrosine kinase inhibitors. Conversely, it is currently still unclear whether mutation status impinges on the prognosis of localized, untreated GISTs. Hence, at present, this variable is not included in decision making for adjuvant therapy. A series of 451 primary localized GISTs were analyzed for KIT, PDGFRA, and BRAF mutations. Univariable and multivariable analyses and a backward selection procedure were used to assess the impact of mutation status on overall survival and to identify prognostically homogenous groups. Mutation was a significant prognostic indicator of overall survival in naive, localized GISTs (P

Original languageEnglish
Pages (from-to)922-930
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume39
Issue number7
DOIs
Publication statusPublished - Jun 29 2015

    Fingerprint

Keywords

  • adjuvant therapy
  • BRAF
  • GIST
  • KIT
  • overall survival
  • PDGFRA
  • population-based study
  • risk assessment
  • SDH, primary, localized, naive

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Rossi, S., Gasparotto, D., Miceli, R., Toffolatti, L., Gallina, G., Scaramel, E., Marzotto, A., Boscato, E., Messerini, L., Bearzi, I., Mazzoleni, G., Capella, C., Arrigoni, G., Sonzogni, A., Sidoni, A., Mariani, L., Amore, P., Gronchi, A., Casali, P. G., ... Dei Tos, A. P. (2015). KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST. American Journal of Surgical Pathology, 39(7), 922-930. https://doi.org/10.1097/PAS.0000000000000418